Complementary capabilities and key strategic alliances

Dr. Simonovich is a specialist in clinical pharmacology and internal medicine, and a physician-researcher specializing in drug development, with over two decades of experience designing and implementing first-in-human clinical trials across oncology, immunology, gene therapy, and rare diseases. He is Section Chief and Full Professor, and coordinates the Clinical Trials Unit at Hospital Italiano de Buenos Aires (HIBA), where he has led studies spanning medical devices and advanced therapies, including the PlasmAr trial (published in NEJM) as first author. He completed the Medical Management Fellowship at Hospital Italiano (2002–2004) and later served as coordinator of the same program. He has twice served as president of the Argentine Association of Experimental Pharmacology and is co-founder of the AAFE SAIC Translational Medicine Council. He is a member of ANMAT's Network of Experts in Pharmacological Research, and a consultant to the United Nations and the Pan American Health Organization.

Dr. Maggini is a physician-scientist with over two decades of experience at the intersection of biomedical research, pharmaceutical industry, and life sciences venture creation. A specialist in internal medicine with a doctoral degree in immunology, he has led medical and scientific strategy across academia, pharma, and early-stage biotechnology. He served as Regional Medical Director for Abbott's Established Pharmaceuticals Division in Latin America, built and directed the Technology Transfer Office at Universidad Austral, and led scientific strategy at Securitas Biosciences, a life sciences venture studio.

Dr. Alonso is a physician and researcher trained in the field of oncology, with extensive experience in preclinical, translational, and clinical research. He has developed cell lines to establish novel tumor models and has contributed to the Mouse Cancer Cell Line Atlas. He has led public–private consortia involving academic institutions, hospitals, and pharmaceutical companies, aimed at identifying new therapeutic targets and developing innovative diagnostic and treatment approaches that have reached the clinical stage.

Dr. Garona is a biotechnologist and translational medicine researcher specializing in oncology. He holds a Ph.D. in Science and Technology and brings nearly 20 years of experience in academic research, drug development, and nutraceuticals through public-private projects and high-tech R&D services for healthcare. He serves as Director of the Biomedical Cancer Research Unit at the Center for Translational Medicine, El Cruce High Complexity Hospital, and as Senior Scientist at the Center for Molecular and Translational Oncology, Quilmes National University. He is also an Independent Researcher at CONICET.

Michael Siani-Rose is an experienced biotechnology entrepreneur and global project manager with over two decades of experience bringing innovation from concept to clinic. He founded and led Theregen, driving a living-cell cardiac patch therapy from a garage startup to IND approval, completing two Phase I human clinical trials, and advancing toward Phase II for ischemic heart disease. At Genentech/Roche, he served as a Global Project Manager in Manufacturing (2013–2022), managing multiple global initiatives in the manufacturing of biologics and small-molecule drugs. He also contributed to digital health and program management at MyoKardia. Currently, he advises emerging entrepreneurs as part of IndieBio's startup accelerator, combining his hands-on experience in R&D, manufacturing, and entrepreneurship to guide early-stage biotech companies from discovery to clinical development.

Dr. Jean-Charles Neels is a cell and molecular biologist with 10 years in startups (from DNA synthesis, chemosensing, brain computer interface). He developed a large network while advising biotech/healthcare investors in the US, UK and Brazil.

Nicolás Kitashima is Operations Advisor at Therasigna Inc., supporting the company's operational strategy, financial planning, administration, compliance, and cross-border coordination. He brings more than fifteen years of experience managing complex initiatives across biosciences, healthcare, academia, and applied technology. His background includes technology transfer, precision medicine, institutional partnerships, and the operational coordination of multi-stakeholder healthcare programs. He holds a degree in Business Administration from the Universidad de Buenos Aires and a Master's in Data Science, Data Mining, and Knowledge Management from Universidad Austral. He is also Adjunct Professor of Project Management for Biomedical Engineering at Universidad Austral.

Federico Asis participates as a consultant at Therasigna Inc., bringing experience from leading law firms, startups, and the biosciences sector. He began his career at Marval O'Farrell Mairal, where he developed a strong foundation in contracts, negotiation, and corporate structuring, before moving into life sciences and emerging technologies. At Therasigna, Federico advises on corporate matters, fundraising, strategic partnerships, intellectual property, and the legal frameworks required to support growth and investor confidence. He holds a law degree from the Universidad de Buenos Aires.

Miguel Oriol Simonovich is a Law student at Facultad de Derecho de la Universidad de Buenos Aires. currently works as a Project Manager at DGSISAN (General Directorate of Health Information Systems), where he previously worked as a Systems Implementation Specialist. He also has professional experience as a Paralegal at Sal & Morchio Law Firm, where he developed valuable knowledge and skills in the legal field. His academic background in Law, combined with his professional experience in both the legal and technology sectors, has allowed him to develop a diverse set of skills and professional interests.